Benzodiazepine deaths increased from April-June 2019 to April-June 2020, with larger increase for illicit benzodiazepine deaths
Findings based on a systematic literature review of studies reporting the use of ketamine, esketamine for treatment-resistant depression
Rates of overdose, mental health crises increased after dose tapering among patients prescribed stable, long-term, higher-dose opioid therapy
No increased risk seen for ADHD, ASD, small for gestational age with prenatal antipsychotics exposure
Current evidence does not support increased suicidality for certain newer antiseizure medications; class warning may not be merited
High-dose buprenorphine protocol well tolerated in patients with untreated opioid use disorder; no reports of respiratory depression or sedation
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
There are still considerable gaps in medication care, with Black enrollees having lower use than Whites
CMS says a final decision on coverage is not likely until next spring
Major changes to prescribing instructions are rare, especially so soon after approval; change could curb the drug's use